Extract

Funding sources: Funding for this study was provided by Celtic Pharma Development Services Bermuda Ltd (an affiliate of Targeted Delivery Technologies Ltd).

Conflicts of interest: R.D. and C.W., none declared; H.T., independent statistical consultant who has undertaken paid work for Celtic Pharma Development Services Ltd; H.‐A.K., employed by Celtic Pharma Development Services Ltd.

Madam, Topical therapy for onychomycosis avoids the adverse systemic effects of oral agents; however, the efficacy rates are disappointingly low compared with oral antifungals.1 The poor outcomes reported with topical agents may be due to the failure of the formulations to achieve adequate concentrations of active ingredient at the site of infection in the nail bed. Our study assessed the efficacy and safety of TDT 067 (Celtic Pharma, Hamilton, Bermuda) — a novel, carrier‐based dosage form of terbinafine in Transfersome® (IDEA AG, Munich, Germany) (1·5% terbinafine spray) — in onychomycosis. Transfersomes are deformable lipid‐based vesicles which have been shown to cross the stratum corneum, and TDT 067 has been developed for the topical delivery of terbinafine to the nail, nail bed and surrounding tissue.

You do not currently have access to this article.